title: Further studies with short duration ribavirin aerosol for the treatment of influenza virus infection in mice and respiratory syncytial virus infection in cotton rats.
abstract: Ribavirin aerosol administration has been shown to be effective in the treatment of respiratory syncytial virus (RSV) infections in infants and in influenza A and B virus infections in young adults. Long treatment schedules and potential for environmental contamination have stimulated the search for alternative dosing schedules. Thus, we attempted to determine the length of time of ribavirin aerosol necessary for effective treatment of influenza and RSV. In RSV-infected cotton rats, aerosolization for just 30 min with high-dose ribavirin (HDR:60 mg ribavirin/ml in reservoir), 3 times daily, reduced viral lung titers/gm of tissue by 1.1 log10. In influenza virus-infected mice, 15 min of aerosolized HDR, 3 times daily, was effective in reducing both mortality and pulmonary virus titers (1.1 log10 reduction). When the intervals between aerosol administration each day were equally divided (i.e., q.8 h), the treatments were most effective. Treatment for 45 min, once daily, was not as effective as divided doses. Calculations of ribavirin concentrations in respiratory secretions following 15 min treatment in mice with HDR indicated that drug levels dropped below the ED50 for influenza viruses after about 9 h. A daily dosage of ribavirin, estimated to be 8-15 mg/kg, was effective for the treatment of influenza and RSV infections.
authors.affiliation: Department of Microbiology and Immunology, Baylor College of Medicine, Houston, TX 77030.
authors.forename: B E
authors.initials: BE
authors.lastname: Gilbert
authors.forename: P R
authors.initials: PR
authors.lastname: Wyde
authors.forename: M W
authors.initials: MW
authors.lastname: Ambrose
authors.forename: S Z
authors.initials: SZ
authors.lastname: Wilson
authors.forename: V
authors.initials: V
authors.lastname: Knight
mesh_terms: D000336:Aerosols; D000818:Animals; D002460:Cell Line; D004285:Dogs; D004334:Drug Administration Schedule; D009980:Influenza A virus / Q000187:drug effects*; D051379:Mice; D009976:Orthomyxoviridae Infections / Q000188:drug therapy*; D012136:Respiratory Syncytial Viruses / Q000187:drug effects*; D010253:Respirovirus Infections / Q000188:drug therapy*; D012254:Ribavirin / Q000627:therapeutic use*; D016205:Sigmodontinae; D013997:Time Factors
chemical_list: D000336:Aerosols; D012254:Ribavirin